f-actin

Cytochalasin B is a mycotoxin binding to the barbed end of actin filaments. It can disrupt the formation of actin polymers (Kd: 1.4-2.2 nM for F-actin).

Defactinib (VS-6063) is a second-generation inhibitor of FAK that inhibits FAK phosphorylation at the Tyr397 site. Defactinib has potential antitumor activity.

Surfactin is a potent cyclic lipopeptide biosurfactants that mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes, with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects.

Surfactin C2 is a useful organic compound for research related to life sciences. The catalog number is T125603 and the CAS number is 171039-18-2.

Surfactin B1 is a useful organic compound for research related to life sciences. The catalog number is T125988 and the CAS number is 136109-79-0.

Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.

Defactinib analogue-1 (Compound 7) serves as a ligand for the target protein FAK, and is utilized in the synthesis of PROTAC FAK degrader 1.

Arthrofactin is a lipopeptide biosurfactant.

Arthrofactin (TFA) is an effective lipopeptide biosurfactant from Pseudomonas sp. MIS38. Its production is associated with various ATP-dependent active transport systems.

Jasplakinolide(Jaspamide), a naturally occurring cyclic peptide from marine sponges, is a potent inducer of actin polymerization.Jasplakinolide exhibits antifungal and antitumor activity and stabilizes pre-existing actin filaments. Jasplakinolide competitively binds to F-actin with the ghost pen cyclic peptide and has a Kd value of 15 nM for F-actin.

Phalloidin, a bicyclic heptapeptide found in Gooseberry, is involved in F-actin staining. Phalloidin is a compound that irreversibly polymerizes actin into microfilaments.Phalloidin interferes with cell motility and growth, and can be used to label cerebral blood vessels.

E0924G is an orally active PPARδ agonist with an EC50 of 2.82 μM. It enhances the upregulation of osteoprotegerin (OPG) expression, with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibits F-actin ring formation in RAW264.7 macrophages. Additionally, E0924G modulates bone density and bone loss in models of ovariectomy (OVX) and age-related osteoporosis.

LSD1-IN-32 (compound 11e) is a potent inhibitor of LSD1, with an IC50 value of 0.99 µM. It effectively impedes RANKL-induced osteoclastogenesis, bone resorption, and F-actin ring formation, indicating its potential use in osteoporosis research.

Pfn1-IN-C1, an inhibitor of Profilin1 (Pfn1), has been shown to reduce the overall level of cellular filamentous (F)-actin, slow EC migration and proliferation, and inhibit the angiogenic ability of EC both in vitro and ex vivo.

Pfn1-IN-C2, an inhibitor of Profilin1 (Pfn1), has been shown to reduce the overall level of cellular filamentous (F)-actin, slow EC migration and proliferation, and inhibit the angiogenic ability of EC both in vitro and ex vivo.

FIPI (5-Fluoro-2-indolyl deschlorohalopemide) is a derivative of halopemide which potently inhibits both PLD1 (IC50 = 25 nM) and PLD2 (IC50 = 20 nM); prevents PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis.

Phalloidin-retramethylrhodamine conjugate is an orange fluorescent probe (ex/em = 546/575 nm) that selectively binds to F-actin. It can be used to localize actin filaments in living or fixed cells, as well as for visualizing individual actin filaments in vitro.

Phallacidin, a phallotoxin family member, targets and binds to F-actin in mushroom toxins.

Phalloidin-FITC is a green fluorescent cytoskeleton stain. Binds and labels F-actin. For most fluorescent imaging applications, cells should be fixed and permeablilized. Excitation/emission maxima λ ~496/516 nm.

Phalloidin-Janelia Fluor®646 is a red fluorescent F-actin probe. Phalloidin-Janelia Fluor®646 is composed of the F-actin probe, Phalloidin, conjugated to Janelia Fluor®646. It is suitable for use in confocal and super-resolution microscopy techniques such as dSTORM. Excitation/emission maximum λ = 646/664 nm.

ROCK-IN-4 is a potent ROCK inhibitor that maintains NO release capacity, reversibly depolymerizes F-actin, and blocks mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 can be utilized to study glaucoma or high intraocular pressure.

DMGF, also known as 7,7-dimethoxyagastisfavone, is a biflavonoid isolated from Taxus × media cv. Hicksii. DMGF induces apoptotic and autophagic cell death. DMGF could effectively attenuate the motility of B16F10 cells, and the results of real-time PCR revealed that DMGF also suppressed the expressions of matrix metalloproteinase-2 (MMP-2). MGF can inhibit the metastasis of highly invasive melanoma cancer cells through the down-regulation of F-actin polymerization DMGF may be further developed to serve as a chemoprevention drug for patients with metastatic melanoma.

Azurin (50-77) is a peptide fragment derived from the copper-containing bacterial protein azurin, present in P. aeruginosa. It exhibits properties that regulate the cell cycle, inhibit cancer proliferation, and manage angiogenesis, proving its potential as an anticancer agent. Specifically, this compound acts as a VEGFR2 inhibitor with an IC20 of approximately 10.7 µM. At a concentration of 20 µM, it effectively induces cell cycle arrest at the G2/M phase in MCF-7 breast cancer cells, while a higher concentration of 50 µM significantly reduces the proliferation of both MCF-7 and ZR-75-1 breast cancer cell lines. Furthermore, Azurin (50-77) impedes VEGF-A-induced capillary tube formation with an IC50 of 12 µM, and alters the cellular and extracellular levels of critical signaling and structural proteins such as F-actin, focal adhesion kinase (FAK), paxillin, and platelet endothelial cell adhesion molecule-1 (PECAM-1) in human umbilical vein endothelial cells (HUVECs) at a concentration of 25 µM. Demonstrating its efficacy in vivo, Azurin (50-77) administered at 10 mg/kg per day notably reduces tumor volume in an MCF-7 mouse xenograft model, highlighting its therapeutic potential.

8-CPT-2'-O-Me-cAMP (250 µM; 1 h) induces Rap1 activation and enhances the recruitment of junction proteins and cortical F-actin in retinal pigment epithelial cells.